Corporate Development Manager

📋 Description

• • Own the end-to-end project management of high-impact corporate development initiatives that shape Healx’s next growth phase, from initial opportunity screening through to signed term sheets and post-deal integration.
• • Build and maintain a living pipeline of strategic options—M&A targets, discovery partnerships, regional out-licensing deals, and co-development alliances—ranked by commercial attractiveness, scientific fit, and patient-impact potential.
• • Serve as the central orchestrator of due-diligence workflows: curate the virtual data-room, coordinate Q&A cycles with external banks and counsel, and keep cross-functional work-streams (IP, pre-clinical, regulatory, finance) on tight timelines so leadership can make rapid, data-driven decisions.
• • Translate complex scientific, financial, and market data into crisp board-quality materials—slide decks, executive memos, valuation models, and scenario analyses—that clearly articulate deal rationale, risk-adjusted returns, and strategic alignment with Healx’s mission to bring therapies to 400 million rare-disease patients.
• • Run rigorous commercial assessments: size addressable patient populations, benchmark deal comparables, model risk-adjusted NPVs, and stress-test assumptions with sensitivity analyses that stand up to investor scrutiny.
• • Cultivate and nurture a network of KOLs, biotech CEOs, venture investors, and pharma BD leaders to generate proprietary deal flow and early insight into emerging science or platform technologies that could accelerate Healx’s pipeline.
• • Partner with Finance and Legal to structure term sheets, negotiate key clauses, and shepherd agreements through internal governance—Scientific Advisory Board, Executive Committee, and Board of Directors—ensuring every transaction advances corporate objectives and capital-efficiency targets.
• • Design and maintain KPI dashboards that track pipeline value creation, deal velocity, and partnership performance, presenting monthly updates to the CEO and Global Head of BD&L to inform resource allocation and strategic pivots.
• • Act as a trusted strategic advisor to the Executive Team during investor roadshows, partnering with Communications to craft compelling equity stories that highlight Healx’s AI platform differentiation and rare-disease focus to potential Series C investors or strategic acquirers.
• • Champion a culture of continuous improvement by documenting best-practice playbooks, instituting stage-gate templates, and mentoring junior analysts—turning ad-hoc deal work into a repeatable, scalable corporate development engine.
• • Flex seamlessly between high-level strategy and hands-on execution: one day you may be modelling a pan-European licensing deal, the next day you are in the lab with scientists to understand translational data that underpins valuation assumptions.
• • Thrive in a fast-moving, mission-driven environment where priorities can shift rapidly; your ability to re-prioritize, communicate transparently, and keep stakeholders aligned will directly influence how quickly rare-disease patients gain access to life-changing therapies.